The ViaLase laser received a CE mark for the treatment of adults with primary open-angle glaucoma, according to a press release.
The device combines a femtosecond laser with image guidance to deliver femtosecond laser, image-guided, high-precision trabeculotomy, also known as FLigHT, the release said.
“ViaLase is thrilled to have received CE mark approval for our ViaLase laser in Europe,” Tibor Juhasz, PhD, founder and CEO of ViaLase, told Healio in an email. “It’s an exciting achievement that puts ViaLase on the path to commercialization in Europe in early 2025. We look